The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Durata Therapeutics, Inc. | Common Stock | 26658A107 | 40,000 | 3,130,824 | SH | SOLE | 3,130,824 | 0 | 0 | ||
| Quintiles Transnational Corp. | Common Stock | 74876Y101 | 84,500 | 1,823,575 | SH | SOLE | 1,823,575 | 0 | 0 | ||
| Intercept Pharmaceuticals | Common Stock | 45845P108 | 9,400 | 137,519 | SH | SOLE | 137,519 | 0 | 0 | ||
| Chimerix, Inc. | Common Stock | 16934W106 | 18,500 | 1,222,943 | SH | SOLE | 1,222,943 | 0 | 0 | ||
| MEI Pharma, Inc. | Common Stock | 57232I303 | 6,200 | 770,000 | SH | SOLE | 770,000 | 0 | 0 | ||
| Sorrento Therapeutics, Inc | Common Stock | 83587F202 | 5,000 | 620,700 | SH | SOLE | 620,700 | 0 | 0 | ||